The DOI matches its Crossref record; 290 of the 290 references it cites were found in a registry or an index.
Stimuli-responsive nanocarriers for drug delivery, tumor imaging, therapy and theranostics
Open accessAbstract
., leading to sensing and signaling, overcoming multidrug resistance, accurate diagnosis and precision therapy. This review has summarized the general strategies of developing stimuli-responsive nanocarriers and recent advances, presented their applications in drug delivery, tumor imaging, therapy and theranostics, illustrated the progress of clinical translation and made prospects.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nanocarriers as an emerging platform for cancer therapy
Peer, D., Karp, J. M., Hong, S., Farokhzad, O. C., Margalit, R., & Langer, R. (2007) · Nature Nanotechnology · doi:10.1038/nnano.2007.387 · Cited by 8,710
Principles of nanoparticle design for overcoming biological barriers to drug delivery
Blanco, E., Shen, H., & Ferrari, M. (2015) · Nature Biotechnology · doi:10.1038/nbt.3330 · Cited by 7,002
Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review
Maeda, H., Wu, J., Sawa, T., Matsumura, Y., & Hori, K. (2000) · Journal of Controlled Release · doi:10.1016/s0168-3659(99)00248-5 · Cited by 6,565
Stimuli-responsive nanocarriers for drug delivery
Mura, S., Nicolas, J., & Couvreur, P. (2013) · Nature Materials · doi:10.1038/nmat3776 · Cited by 6,289
Cancer nanomedicine: progress, challenges and opportunities
Shi, J., Kantoff, P. W., Wooster, R., & Farokhzad, O. C. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2016.108 · Cited by 5,873
Why Do Cancers Have High Aerobic Glycolysis?
Gatenby, R. A., & Gillies, R. J. (2004) · Nature reviews. Cancer · doi:10.1038/nrc1478 · Cited by 4,784
Exploiting tumour hypoxia in cancer treatment
Brown, J. M., & Wilson, W. R. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1367 · Cited by 2,828
Accumulation of sub-100 nm polymeric micelles in poorly permeable tumours depends on size
Cabral, H., Matsumoto, Y., Mizuno, K., Chen, Q., Murakami, M., Kimura, M., Terada, Y., Kano, M. R., Miyazono, K., Uesaka, M., et al. (2011) · Nature Nanotechnology · doi:10.1038/nnano.2011.166 · Cited by 2,429
Reactive oxygen species generating systems meeting challenges of photodynamic cancer therapy
Zhou, Z., Song, J., Nie, L., & Chen, X. (2016) · Chemical Society Reviews · doi:10.1039/c6cs00271d · Cited by 2,098
Helmlinger, G., Yuan, F., Dellian, M., & Jain, R. K. (1997) · Nature Medicine · doi:10.1038/nm0297-177 · Cited by 1,628
Cited by
Shi, Y., van der Meel, R., Chen, X., & Lammers, T. (2020) · Theranostics · doi:10.7150/thno.49577 · Cited by 868
Glioblastoma multiforme (GBM): An overview of current therapies and mechanisms of resistance
Wu, W., Klockow, J. L., Zhang, M., Lafortune, F., Chang, E., Jin, L., Wu, Y., & Daldrup-Link, H. E. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105780 · Cited by 805
Advanced application of stimuli-responsive drug delivery system for inflammatory arthritis treatment
Zhang, M., Hu, W., Cai, C., Wu, Y., Li, J., & Dong, S. (2022) · Materials Today Bio · doi:10.1016/j.mtbio.2022.100223 · Cited by 394
Recent Progress in Nanostructured Smart Drug Delivery Systems for Cancer Therapy: A Review
Khan, M. I., Hossain, M. I., Hossain, M. K., Rubel, M. H. K., Hossain, K. M., Mahfuz, A. M. U. B., & Anik, M. I. (2022) · ACS Applied Bio Materials · doi:10.1021/acsabm.2c00002 · Cited by 370
Nanotechnology-based delivery of CRISPR/Cas9 for cancer treatment
Xu, X., Liu, C., Wang, Y., Koivisto, O., Zhou, J., Shu, Y., & Zhang, H. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.113891 · Cited by 289
Harnessing Endogenous Stimuli for Responsive Materials in Theranostics
Cook, A. B., & Decuzzi, P. (2021) · ACS Nano · doi:10.1021/acsnano.0c09115 · Cited by 262
Metallodrugs in cancer nanomedicine
Peña, Q., Wang, A., Zaremba, O., Shi, Y., Scheeren, H. W., Metselaar, J. M., Kiessling, F., Pallares, R. M., Wuttke, S., & Lammers, T. (2022) · Chemical Society Reviews · doi:10.1039/d1cs00468a · Cited by 259
Block copolymer solution self‐assembly: Recent advances, emerging trends, and applications
Karayianni, M., & Pispas, S. (2021) · Journal of Polymer Science · doi:10.1002/pol.20210430 · Cited by 257
Cai, S., Liu, J., Ding, J., Fu, Z., Li, H., Xiong, Y., Lian, Z., Yang, R., & Chen, C. (2022) · Angewandte Chemie International Edition · doi:10.1002/anie.202204502 · Cited by 255
Lu, Y., Pan, Q., Gao, W., Pu, Y., Luo, K., He, B., & Gu, Z. (2022) · Biomaterials · doi:10.1016/j.biomaterials.2021.121335 · Cited by 149
Zhang, W., Taheri-Ledari, R., Ganjali, F., Afruzi, F. H., Hajizadeh, Z., Saeidirad, M., Qazi, F. S., Kashtiaray, A., Sehat, S. S., Hamblin, M. R., et al. (2022) · Heliyon · doi:10.1016/j.heliyon.2022.e09577 · Cited by 79
RetractedSouri, M., Soltani, M., & Moradi Kashkooli, F. (2021) · Scientific Reports · doi:10.1038/s41598-021-98554-z · Cited by 61
Clinical translation of nanomedicines for brain diseases: Current challenges and future directions
Wang, G., Wang, N., Xia, X., Ismail, M., & Shi, B. (2026) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.114426 · Cited by 33
Nanomaterials Based on Functional Polymers for Sensitizing Cancer Radiotherapy
Lin, J., Yin, M., Liu, X., Meng, F., & Luo, L. (2022) · Macromolecular Rapid Communications · doi:10.1002/marc.202200194 · Cited by 18
Tanaka, M., Araujo, A. C., Valenti, V. E., Guiguer, E. L., Catharin, V. C. S., Gualhardi, C. M., de Souza Bastos Mazuqueli Pereira, E., de Alvares Goulart, R., de Argolo Haber, R. S., de Carvalho, A. C. A., et al. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27052370 · Cited by 13
Tao, J., Ning, W., Lu, W., Wang, R., Zhou, H., Zhang, H., Xu, J., Wang, S., Teng, Z., & Wang, L. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.01.058 · Cited by 10
Metadata
- Authors
- Mi, P.
- Venue
- Theranostics
- Publisher
- Ivyspring International Publisher
- Published
- 2020
- Volume
- 10
- Issue
- 10
- Pages
- 4557-4588
- ISSN
- 1838-7640 (ISSN-L)
- OpenAlex
- W3015804616
- Cited by
- 830
- References
- 290
- FWCI
- 18.35
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.